Adolor Corporation Initiates Clinical Testing In Opioid Bowel Dysfunction Program

Adolor Corporation (NasdaqGM:ADLR) announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD). The Phase 1, single ascending dose trial in healthy volunteers will assess safety and tolerability of the compound and will be followed by a multiple ascending dose study in early 2010.

Read more: 
Adolor Corporation Initiates Clinical Testing In Opioid Bowel Dysfunction Program

Related posts:

1. Targacept Initiates Phase 2 Study Of TC-5619 In Cognitive Dysfunction In Schizophrenia Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, announced that it has initiated a Phase 2 clinical proof of concept...
2. AFFiRiS AG: Interim Analysis Of Clinical Phase I Data Triggered Decision To Move Alzheimer’s Vaccine Candidate AD02 Into Clinical Phase II Testing AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II...
3. Tokai Pharmaceuticals Initiates ARMOR Clinical Development Program For TOK-001; First Ever Multi-Target Investigational Drug For Prostate Cancer Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the...
4. Millennium Initiates First Clinical Trial With The First Oral Proteasome Inhibitor Millennium: The Takeda Oncology Company announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the...
5. Boehringer Ingelheim Initiates First Phase III Clinical Trial In Ovarian Cancer Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced...
6. Avedro Initiates Keraflex(R) KXL Clinical Trials For Treating Keratoconus During the 5th International Congress of Corneal Cross Linking for Keratoconus in Leipzig, Germany on December 5th, Avedro presented encouraging early clinical results for treating keratoconus, a progressive disease of...
7. Ambit Biosciences Initiates First Phase 2 Clinical Trial Of AC220 In Acute Myeloid Leukemia Ambit Biosciences Corporation announced the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2...
8. Ipsen Initiates An Advanced Endometrial Cancer Program With BN83495, Its First-in-Class Steroid Sulfatase Inhibitor First Patient Dosed In Phase II Ipsen (Paris:IPN) announced the initiation of an international, multi-center, controlled, randomized Phase II clinical trial to evaluate the safety and efficacy of BN83495, its investigational first-in-class steroid sulfatase (STS) inhibitor,...
9. Esperion Therapeutics Initiates Phase I Clinical Study For ETC-1002 Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, announced that the company has initiated a Phase I clinical study...
10. New York Times Examines HIV Testing Program In China New York Times Examines HIV Testing Program In ChinaThe New York Times examines an HIV prevention program in China aimed at promoting blood screening that has led "more than 110,000...
11. Biovitrum Advances Novel Factor VIII Long-Acting Hemophilia A Therapy Into Clinical Trials Biovitrum AB (publ) (STO: BVT) announced that the first patient was dosed in a phase I/IIa study of its long-acting fully-recombinant Factor VIII Fc fusion (rFVIIIFc) protein. The phase I/IIa...
12. InVivo Therapeutics Corporation Files FDA Application For Human Studies For Spinal Cord Injury Treatment InVivo Therapeutics Corporation has filed an Investigational Device Exemption application with the Food and Drug Administration requesting permission to advance to human clinical studies. InVivo is currently conducting its third...
13. Echo Therapeutics Announces Positive Results Of A Clinical Study Testing Symphony(TM) TCGM System In Patients With Type 1 And Type 2 Diabetes Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System...
14. Modernizing The Treatment Of Sexual Dysfunction In Men Modern, couple-oriented treatment for male sexual dysfunction takes the psychosocial aspects of sex into account, as well as focussing on the purely physical aspects of the problem. The importance of...
15. Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance For Proposed INTERCEPT Blood System Phase III Trial Design Cerus Corporation (NASDAQ:CERS) announced that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III...

« GPs Key To Meeting HIV Changes And Challenges, Australian How A Gel Can Help You Lose Weight »